Literature DB >> 19656996

Pathogenetic and clinical relevance of microRNAs in colorectal cancer.

Nicola Valeri1, Carlo M Croce, Muller Fabbri.   

Abstract

Colorectal cancer (CRC) has been described as a multistep disease due to the progressive accumulation of mutations and chromosomal rearrangements involving critical oncogenes or oncosuppressors. MicroRNAs (miRNAs) are a class of small interfering RNAs frequently involved in the pathogenesis of cancer. Several genome-wide profiling studies have identified miRNAs deregulated in colorectal cancer. Many of these deregulated miRNAs contribute to CRC tumorigenesis and may help to understand CRC pathogenesis, prognosis and response to treatment. This review will focus on common mechanisms involved in miRNA alterations in CRC, their functional implication in CRC development and the potential use of miRNAs as prognostic and predictive surrogate markers for the management of CRC patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19656996

Source DB:  PubMed          Journal:  Cancer Genomics Proteomics        ISSN: 1109-6535            Impact factor:   4.069


  19 in total

1.  Species-specific function of microRNA-7702 in human colorectal cancer cells via targeting TADA1.

Authors:  Han Liu; Dongdong Li; Hua Fang; Junnan Ning
Journal:  Am J Transl Res       Date:  2018-08-15       Impact factor: 4.060

2.  microRNA expression pattern and its alteration following celecoxib intervention in human colorectal cancer.

Authors:  Wei Chang Chen; Mao Song Lin; Yu Lan Ye; Heng Jun Gao; Zhen Yun Song; Xiao Ying Shen
Journal:  Exp Ther Med       Date:  2012-03-30       Impact factor: 2.447

3.  MiR-19a suppresses ferroptosis of colorectal cancer cells by targeting IREB2.

Authors:  Hongwei Fan; Rong Ai; Suen Mu; Xuemin Niu; Zhengrong Guo; Lin Liu
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

4.  An evaluation and replication of miRNAs with disease stage and colorectal cancer-specific mortality.

Authors:  Martha L Slattery; Jennifer S Herrick; Lila E Mullany; Nicola Valeri; John Stevens; Bette J Caan; Wade Samowitz; Roger K Wolff
Journal:  Int J Cancer       Date:  2014-12-16       Impact factor: 7.396

5.  MicroRNA Dysregulation in Colon Cancer Microenvironment Interactions: The Importance of Small Things in Metastases.

Authors:  Sabina Pucci; Paola Mazzarelli
Journal:  Cancer Microenviron       Date:  2011-02-16

6.  Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer.

Authors:  M Pichler; E Winter; M Stotz; K Eberhard; H Samonigg; S Lax; G Hoefler
Journal:  Br J Cancer       Date:  2012-05-01       Impact factor: 7.640

7.  Circulating miR-182 is a biomarker of colorectal adenocarcinoma progression.

Authors:  Lisa Perilli; Caterina Vicentini; Marco Agostini; Silvia Pizzini; Marco Pizzi; Edoardo D'Angelo; Stefania Bortoluzzi; Susanna Mandruzzato; Enzo Mammano; Massimo Rugge; Donato Nitti; Aldo Scarpa; Matteo Fassan; Paola Zanovello
Journal:  Oncotarget       Date:  2014-08-30

8.  Reference miRNAs for colorectal cancer: analysis and verification of current data.

Authors:  E Danese; A M Minicozzi; M Benati; E Paviati; G Lima-Oliveira; M Gusella; F Pasini; G L Salvagno; M Montagnana; G Lippi
Journal:  Sci Rep       Date:  2017-08-21       Impact factor: 4.379

9.  MicroRNAs as Novel Biomarkers in Colorectal Cancer.

Authors:  Sonja Hrašovec; Damjan Glavač
Journal:  Front Genet       Date:  2012-10-19       Impact factor: 4.599

10.  MicroRNA-135b promotes cancer progression by acting as a downstream effector of oncogenic pathways in colon cancer.

Authors:  Nicola Valeri; Chiara Braconi; Pierluigi Gasparini; Claudio Murgia; Andrea Lampis; Viola Paulus-Hock; Jonathan R Hart; Lynn Ueno; Sergei I Grivennikov; Francesca Lovat; Alessio Paone; Luciano Cascione; Khlea M Sumani; Angelo Veronese; Muller Fabbri; Stefania Carasi; Hansjuerg Alder; Giovanni Lanza; Roberta Gafa'; Mary P Moyer; Rachel A Ridgway; Julia Cordero; Gerard J Nuovo; Wendy L Frankel; Massimo Rugge; Matteo Fassan; Joanna Groden; Peter K Vogt; Michael Karin; Owen J Sansom; Carlo M Croce
Journal:  Cancer Cell       Date:  2014-04-14       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.